Impact of HPV vaccination with Gardasil® in Switzerland.

Fiche du document

Auteurs
Date

22 décembre 2017

Discipline
Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12879-017-2867-x

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/29273004

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1471-2334

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B488477F86718

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Adolescent; Child; Chlamydia Infections/diagnosis; Chlamydia Infections/epidemiology; Chlamydia trachomatis/genetics; Chlamydia trachomatis/isolation & purification; DNA, Viral/genetics; DNA, Viral/metabolism; Female; Follow-Up Studies; Genotype; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/immunology; Humans; Papillomaviridae/genetics; Papillomaviridae/isolation & purification; Papillomavirus Infections/diagnosis; Papillomavirus Infections/epidemiology; Papillomavirus Infections/prevention & control; Papillomavirus Vaccines/immunology; Surveys and Questionnaires; Switzerland/epidemiology; Uterine Cervical Neoplasms/diagnosis; Uterine Cervical Neoplasms/prevention & control; Vaccination; Anyplex II™ HPV28; Cervical cancer screening; Chlamydia trachomatis; Gardasil®; HPV genotyping; HPV vaccine; Human papillomavirus; PGMY-CHUV; Real-time PCR; Segmented logistic regression

Sujets proches En

Papillomaviridae Infectious human wart virus Human wart virus Human papilloma virus Papillomavirus HPV (Virus) Wart virus Papovaviruses Papilloma viruses

Citer ce document

M. Jacot-Guillarmod et al., « Impact of HPV vaccination with Gardasil® in Switzerland. », Serveur académique Lausannois, ID : 10.1186/s12879-017-2867-x

Métriques

Partage / Export

Résumé 0

Gardasil®, a quadrivalent vaccine targeting low-risk (6, 11) and high-risk (16, 18) human papillomaviruses (HPV), has been offered to 11-14 year-old schoolgirls in Switzerland since 2008. To evaluate its success and its potential impact on cervical cancer screening, HPV genotypes were examined in 18-year-old girls five years later (sub-study 1) and in outpatients participating to cervical cancer screening before and after vaccine implementation (sub-study 2). For sub-study 1, 3726 females aged 18 in 2013 were invited to fill a questionnaire on personal demographics and HPV risk factors and to provide a self-collected cervicovaginal sample for HPV genotyping and Chlamydia trachomatis PCR. Personal data were evaluated by univariable and multivariable statistics. In sub-study 2, the proportion of the vaccine-type HPV among anogenital HPV was examined with archived genotyping data of 8039 outpatients participating to cervical cancer screening from 1999 till 2015. The yearly evolution of this proportion was evaluated by segmented logistic regression. 690 (18.5%) women participated to sub-study 1 and 327 (8.8%) provided a self-collected sample. Prevalence of Chlamydia trachomatis (4.6%) and demographics confirmed that the subjects were representative of sexually-active Swiss young women. Vaccine (five-year coverage: 77.5%) was preferentially accepted by contraceptive-pill users (P = 0.001) and samples were mainly provided by sexually-active subjects (P < 0.001). The proportion (4%) of the vaccine-type HPV in this population was lower than in sub-study 2 outpatients (n = 849,

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Sur les mêmes disciplines

Exporter en